Halozyme (NASDAQ: HALO) shareholders approve directors, pay plan and Ernst & Young
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Halozyme Therapeutics, Inc. reported the results of its Annual Meeting of Stockholders held on May 5, 2026. Of 118,474,300 common shares outstanding as of the record date, 104,138,244 shares were represented, meaning a large majority of shareholders participated.
Stockholders elected Bernadette Connaughton and Matthew L. Posard as Class I directors for three-year terms, with each receiving more than a majority of the outstanding shares. They also approved, on an advisory basis, the compensation of the company’s named executive officers and ratified the selection of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Shares outstanding: 118,474,300 shares
Shares represented: 104,138,244 shares
Votes for Connaughton: 89,053,734 votes
+3 more
6 metrics
Shares outstanding
118,474,300 shares
Common stock outstanding as of the record date
Shares represented
104,138,244 shares
Common stock represented at the annual meeting
Votes for Connaughton
89,053,734 votes
Election of Class I director Bernadette Connaughton
Votes for Posard
82,739,433 votes
Election of Class I director Matthew L. Posard
Say-on-pay support
84,682,518 votes for
Advisory vote on compensation of named executive officers
Auditor ratification support
103,197,579 votes for
Ratification of Ernst & Young LLP for fiscal year ending December 31, 2026
Key Terms
Annual Meeting of Stockholders, broker non-votes, advisory vote, independent registered public accounting firm, +1 more
5 terms
Annual Meeting of Stockholders financial
"On May 5, 2026, Halozyme Therapeutics, Inc. held its Annual Meeting of Stockholders."
broker non-votes financial
"The number of votes cast for and against and the number of abstentions and broker non-votes with respect to each matter voted upon are set forth below."
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
advisory vote financial
"Proposal 2: The advisory vote on the compensation of the Company's named executive officers was as follows"
An advisory vote is a shareholder poll that expresses investors’ approval or concern about a company’s policy, executive pay, board decisions or other governance matters but does not legally force the company to act. Think of it like a customer survey: it signals investor sentiment and can pressure management to change course, so investors watch the result as a guide to future governance, risk and potential shifts in strategy.
independent registered public accounting firm financial
"Proposal 3: The vote on a proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was as follows"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
Class I directors financial
"Proposal 1: Election of two Class I directors to hold office for a three-year term"
Class I directors are the subset of a company’s board whose terms expire at a specific annual meeting under a staggered election system that divides directors into multiple groups with different re-election years. For investors this matters because staggered classes slow how quickly shareholders can replace the board, affecting takeover risk, governance change and the pace of corporate decisions — like rotating only part of a team instead of swapping everyone at once.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
____________________________________________
FORM 8-K
_____________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
| Date of Report (Date of Earliest Event Reported): | ||||||||
(Exact name of registrant as specified in its charter)
________________________
Commission File Number 001-32335
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | |||||||
| (Zip Code) | ||||||||
| (Address of principal executive offices) | ||||||||
(858 ) 794-8889
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 ( §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ( §240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security Holders.
On May 5, 2026, Halozyme Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders. Of the 118,474,300 shares of the Company's common stock outstanding as of the record date, 104,138,244 shares were represented at the annual meeting.
The stockholders considered three proposals at the meeting, each of which is described in more detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 23, 2026. The number of votes cast for and against and the number of abstentions and broker non-votes with respect to each matter voted upon are set forth below..
Proposal 1: Election of two Class I directors to hold office for a three-year term expiring at the 2029 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified:
| Names | Votes For | Votes Against | Abstain | Broker Non-Votes | ||||||||||||||||||||||
Bernadette Connaughton | 89,053,734 | 5,068,160 | 127,131 | 9,889,219 | ||||||||||||||||||||||
Matthew L. Posard | 82,739,433 | 10,236,878 | 1,272,714 | 9,889,219 | ||||||||||||||||||||||
Each of the foregoing candidates was elected and each received affirmative votes from more than a majority of the outstanding shares.
Proposal 2: The advisory vote on the compensation of the Company's named executive officers was as follows:
| Votes For | Votes Against | Abstain | Broker Non-Votes | |||||||||||||||||
| 84,682,518 | 9,311,426 | 255,081 | 9,889,219 | |||||||||||||||||
The foregoing proposal was approved.
Proposal 3: The vote on a proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was as follows:
| Votes For | Votes Against | Abstain | Broker Non-Votes | |||||||||||||||||
| 103,197,579 | 849,433 | 91,232 | --- | |||||||||||||||||
The foregoing proposal was approved.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| HALOZYME THERAPEUTICS, INC. (Registrant) | |||||||||||||||||
| Dated: | May 7, 2026 | By: | /s/ Mark Snyder | ||||||||||||||
| Mark Snyder | |||||||||||||||||
| Senior Vice President, General Counsel and Corporate Secretary | |||||||||||||||||
FAQ
What did Halozyme Therapeutics (HALO) stockholders vote on at the 2026 annual meeting?
Stockholders voted on three items: electing two Class I directors, an advisory vote on executive compensation, and ratifying Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. All three proposals received sufficient support for approval.
Were Halozyme Therapeutics (HALO) director nominees elected at the 2026 annual meeting?
Yes. Bernadette Connaughton received 89,053,734 votes for and Matthew L. Posard received 82,739,433 votes for. Each nominee obtained affirmative votes from more than a majority of the outstanding shares, securing election as a Class I director for a three-year term expiring at the 2029 meeting.